The effect of CUTICERIN® with or without a Regenerative Epithelial Suspension (RES™), on pigmentation of donor sites in children: The pilot randomised DRESSIng Trial
A pilot randomised trial evaluating the effect of CUTICERIN® with or without a Regenerative Epithelial Suspension (RES™), on pigmentation of paediatric, split-thickness skin graft donor sites: The DRESSIng Trial, a pilot randomised trial.
Department of Industry , Innovation and Science
40 participants
Jul 21, 2020
Interventional
Conditions
Summary
Abnormal donor site colour causes much distress to children and their families and remains a difficult problem for clinicians to treat. In children receiving a skin graft to treat a burn injury, the donor site is a source of pain, itch and at risk of scarring. The current the donor site dressings mainly enable faster wound healing. None of the dressings address the colour restoration in donor sites. The Regenerative Epithelial Suspension (RES™) prepared using the RECELL® Autologous Cell Harvesting (ACH) device has been in clinical use for over a decade. Once prepared a mixture of epithelial cells is applied to the wound. There are few studies that evaluate donor site wound management in children with RES™. Recently, in a study comparing RES™ with skin grafts (control group), wounds treated with RES™ had comparable healing, with significantly smaller donor site, less pain and better appearance relative to the control group. The RECELL® ACH device is easy to use, requires smaller donor skin sample, fewer dressing changes, lower pain scores and as such, may incur less cost in the overall burn wound treatment. Delayed wound healing is associated with higher scarring risk in children. Graft loss results in delayed healing. Current standard practice at the study site includes the topical application of ARTISS® (biological product that acts as an adhesive agent) onto the recipient site before skin graft. The fibrin facilitates adhesion of the sheet graft to the recipient site. The combination of RES™ with skin graft was reported as both effective and safe in adult studies. However, the effect of RES™ on the skin graft, recipient site graft takes and colour in children has not been assessed in the published literature. This study aims to evaluate the efficacy of a RES™ on donor site colour at 12 months after skin graft and recipient site graft take in children.
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The initial application of intervention will be under general anaesthesia by the burns surgical team using sterile technique. ARM1: Donor Site Intervention. The intended donor site will be marked to a maximum area of 320sqcm. Following sterile skin preparation, a donor skin biopsy will be harvested with a pneumatic dermatome(Zimmer Inc., Warsaw, IN, USA) at depth of 0.018cm(0.007in). Topical application of local aneasthesia (bupivacaine 0.25% with epinephrine 1:200,000 AstraZeneca Pty Ltd, North Ryde, NSW, Australia) , calculated at a maximum safe dose(2 to 2.5 mg/kg) will facilitate pain relief and haemostasis at the newly created donor site wound (DSW). A three step degradation process with the RECELL® Autologous Cell Harvesting (ACH) device transforms the skin biopsy in a Regenerative Epithelial Suspension (RES™) as per manufacturer specifications. The RES™ will the be applied by droplet or spray onto the donor site wound and covered with Cuticerin®, a low-adherent , impregnate dressing composed of smooth acetate fabric coated in a water repellant ointment containing petrolatum, paraffin and Eucerite®. The sequence of outer layers will be Allevyn® followed by Hypafix®. The first change of dressing will be a week post-skin graft . Thereafter Xeroform® will be applied to the DSW every 2-3 days until greater than 95% re-epithelialisation is confirmed by a burns clinician. Xeroform® is a non-adherent, petrolatum coated fine mesh gauze that contains 3% bismuth tribromophenate. Recipient Site Intervention: Skin graft recipient site will be marked to maximum of 400sqcm for evaluation. RES™ will then be topically applied to the recipient site followed by perforated, split-thickness skin sheet graft with or without ARTISS®, a fibrin sealant. The graft will be fixed to normal skin with or without Histoacryl® tissue glue. The sequence of secondary, outer dressings will be Mepitel® , Acticoat® , Hypafix® . Depending on the site of the skin graft negative pressure wound therapy may also be applied as per clinician assessment. Change of dressing schedule and application of Xeroform® is as described for the donor site wound. Intervention fidelity will be assessed using a questionnaire that evaluates each step of dressing application by an investigator aligned with the study..
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620000227998